Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Cost of Revenue (2018 - 2025)

UroGen Pharma (URGN) has disclosed Cost of Revenue for 7 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 33.1% year-over-year to $3.3 million, compared with a TTM value of $12.4 million through Dec 2025, up 40.15%, and an annual FY2025 reading of $12.4 million, up 40.15% over the prior year.
  • Cost of Revenue was $3.3 million for Q4 2025 at UroGen Pharma, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.6 million in Q2 2025 and bottomed at $897000.0 in Q1 2021.
  • Average Cost of Revenue over 5 years is $2.2 million, with a median of $2.3 million recorded in 2022.
  • The sharpest move saw Cost of Revenue surged 302.59% in 2021, then dropped 23.71% in 2024.
  • Year by year, Cost of Revenue stood at $1.6 million in 2021, then soared by 42.42% to $2.3 million in 2022, then rose by 1.02% to $2.3 million in 2023, then grew by 8.09% to $2.5 million in 2024, then soared by 33.1% to $3.3 million in 2025.
  • Business Quant data shows Cost of Revenue for URGN at $3.3 million in Q4 2025, $3.3 million in Q3 2025, and $3.6 million in Q2 2025.